NCT07053709Not yet recruiting
Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD)
Source: ClinicalTrials.gov · Last updated 13 Jan 2026
Brief summary (registry, in English)
Due to the established correlation between serum uric acid (SUA) levels and metabolic associated fatty liver disease (MAFLD), this study aims to screen for hyperuricemia in all patients diagnosed with MAFLD. The ultimate goal is to support the management of MAFLD and improve patients' quality of life by reducing both morbidity and mortality.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 21 Jun 2025
- Start date
- 1 Nov 2026
- Primary completion date
- 1 Nov 2026
- Lead sponsor
- Assiut University
- Diseases
- Fatty liver disease (MASLD/MASH)
- NCT number
- NCT07053709
What you commit to
- Study type: Observational
- Planned participants: 200
- From 1 Nov 2026 to the primary completion date, 1 Nov 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with fatty liver disease who have previously undergone bariatric surgery.
Other illness
- Presence of any malignancy.
- Diagnosis of type 1 diabetes mellitus (T1DM).
Age
- Patients aged 18 years or younger.
Other
- Pregnant individuals.
Who the study is looking for
- Adults aged over 18 years.
- Diagnosis of MAFLD based on abdominal ultrasonography or other validated imaging techniques.
Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.